Searchable abstracts of presentations at key conferences in endocrinology

ea0052p15 | (1) | UKINETS2017

Platinum-etoposide chemotherapy for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC): A survey of clinical practice

Lamarca Angela , Frizziero Melissa , Barriuso Jorge , McNamara Mairead G , Hubner Richard A , Valle Juan W

Introduction: Platinum-etoposide chemotherapy is a globally established chemotherapy combination for EP-G3-NEC. However, there are many different schedules for such chemotherapy, and the preferred one for EP-G3-NEC has not been established.Methods: An international survey was created, and completed by colleagues with an expertise in the field of neuroendocrine neoplasms. The aim was to explore which schedules of platinum-etoposide chemotherapy are used a...

ea0068p14 | Abstracts | UKINETS2019

Liver embolisation for patients diagnosed with neuroendocrine neoplasms: systematic review and meta-analysis of the literature

Kanabar Rahul , Barriuso Jorge , McNamara Mairead , Mansoor Was , Hubner Richard , Valle Juan , Lamarca Angela

Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN), especially in the presence of carcinoid syndrome. It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs.Methods: Eligible studies (identified...

ea0068p6 | Abstracts | UKINETS2019

Hepatic arterial embolisation for patients diagnosed with neuroendocrine neoplasms: experience from a European Neuroendocrine Tumour Society centre of excellence

Nuttall Christina , Lamarca Angela , McNamara Mairead , Barriuso Jorge , Lawrance Jeremy , Mullan Damian , Mansoor Was , Valle Juan , Hubner Richard

Background: Hepatic arterial embolisation (HAE) is a recommended treatment option for patients with neuro-endocrine neoplasms (NENs) and liver metastasis. We aimed to describe outcomes after HAE for NENs at a single United Kingdom centre and investigate the influence of tumour characteristics.Methods: Retrospective analysis of sequential patients with NENs undergoing HAE at The Christie NHS Foundation Trust between 2004 and 2018. Primary end points were ...

ea0046p9 | (1) | UKINETS2016

Whole-exome sequencing (WES) of samples from patients with advanced pancreatic neuroendocrine tumours (pNETs) with exceptional responses vs. poor responders to targeted therapies; a TransNET study

Barriuso Jorge , Lamarca Angela , McNamara Mairead , Burgis Timothy , Manoharan Prakash , Hayes Andrew , Mansoor Wasat , Hubner Richard , Valle Juan

Background: Despite encouraging advances in the systemic therapy options for patients with pNETs (sunitinib and everolimus), no predictive biomarkers have been established for these drugs. We aimed to identify distinctive genomic alterations associated with benefit from treatment in patients with pNETs, by comparing exceptional-responders (ER) to poor-responders (PO).Methods: Patients who achieved an objective radiological response (complete or partial) ...

ea0052p21 | (1) | UKINETS2017

Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence

Frizziero Melissa , Lamarca Angela , Kordatou Zoe , Barriuso Jorge , Nuttall Christina , McNamara Mairead G. , Hubner Richard A. , Mansoor Wasat , Manoharan Prakash , Valle Juan W.

Introduction: Platinum-etoposide is considered standard-of-care first-line treatment for patients diagnosed with advanced EP-PD-NECs. The optimal platinum-etoposide schedule remains undefined; carboplatin is often substituted for cisplatin, although quality data is lacking.Methods: Electronic records of patients with advanced EP-PD-NEC treated with carboplatin-etoposide (06/09-02/17) were reviewed retrospectively, with aim to provide real-life efficacy/s...

ea0068p12 | Abstracts | UKINETS2019

Systemic chemotherapy for inoperable Goblet Cell Adenocarcinomas (GCAs)

Barriuso Jorge , Lamarca Angela , Martin Amy , Chakrabarty Bipasha , Clouston Hamish , Mullamitha Saifee , McNamara Mairead , Marti-Marti Francisca , Hubner Richard , Saunders Mark , O'Dwyer Sarah , Braun Michael , Valle Juan

Background: Appendiceal GCAs (previously known as Goblet Cell Carcinoids) are considered to have an unpredictable behaviour; even in node-negative patients, metastases mainly local to the adjacent peritoneum are seen. The systemic chemotherapy (scx) is often borrowed from colon cancer regimens. We designed a retrospective study with the aim of describing the use of scx in these rare malignancies in our institution.Methods: Data from all consecutive cases...

ea0060p07 | (1) | UKINETS2018

Bone metastases (BMs) in patients with neuroendocrine neoplasms (NENs): Prevalence and clinical management in a tertiary cancer centre

Lim Kok Haw Jonathan , Raja Hussain , D'Arienzo Paolo , Barriuso Jorge , McNamara Mairead G , Hubner Richard A , Mansoor Was , Valle Juan W , Lamarca Angela

Background: Bone metastases (BMs) are rare in neuroendocrine neoplasms (NENs). There is no global consensus on the optimal management, and treatment is often extrapolated from experience in other tumour groups. The aim of this study was to review the current management and outcomes of patients with BMs in NENs.Method: A retrospective study was performed of all patients with NENs, except G3 lung NENs, treated at a tertiary centre from April 2002–Marc...

ea0060p18 | (1) | UKINETS2018

The impact of 68Ga-based PET-CT scanning on the management of patients with sporadic pancreatic neuroendocrine tumours (pNETs)

Cuthbertson Daniel , Barriuso Jorge , Pizanais Michail , Jaffa Matthew , Lamarca Angela , Vivian Gillian , Halloran Tom , Westwood Tom , Prachalias Andreas , O'Reilly Derek , Weismann Hulya , Martin Wendy , Vinjamuri Sobhan , Pritchard D Mark , Hubner Richard , Srirajaskanthan Raj , Ramage John , Raraty Mike , Ganeh Paula , Fenwick Steve , Valle Juan , Yip Vincent

Background: Pancreatic neuroendocrine tumours (panNETs) are rare tumours (prevalence 4/100,000). Diagnosis and staging of panNETs requires biochemical screening, cross-sectional imaging (with CT/MRI), endoscopic ultrasound (EUS) and where available, functional imaging using 68Ga-labelled synthetic octreotide analogues using PET-CT due to its reported higher sensitivity and specificity.Methods: A retrospective, electronic case note study was ca...

ea0060p30 | (1) | UKINETS2018

The impact of 68Ga-based PET-CT scanning on the management of patients with familial pancreatic neuroendocrine tumours (panNETs)

Cuthbertson Daniel , Barriuso Jorge , Pizanias Michail , Jaffa Matthew , Nuttall Christina , Vivian Gillian , Halloran Tom , Westwood Tom , Prachalias Andreas , Lalloo Fiona , Weismann Hulya , Martin Wendy , Vinjamuri Sobhan , Mark Pritchard D. , Fenwick Steve , Ganeh Paula , Raraty Mike , McNamara Mairead , Srirajaskanthan Raj , Ramage John , Manoharan Prakash , Yip Vincent

Background: Pancreatic neuroendocrine tumours (panNETs) may arise as part of an underlying genetic condition such as multiple endocrine neoplasia type 1 (MEN type 1). The value of functional imaging using 68Ga-labelled synthetic octreotide analogues using PET-CT has not been extensively evaluated in patients with MEN1 to determine its value.Methods: We investigated the effect of 68Ga-based PET-CT imaging on patient management in pat...